Table 3 Association between clinicopathological features and survival parameters
Clinicopathological features | PFS | OS | ||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age (≥ 65 years) | 0.741 (0.460–1.192) | 0.216 | 0.653 (0.377–1.131) | 0.128 |
ECOG PS (2) | 9.725 (4.78–19.785) | < 0.001 | 5.200 (2.711–9.974) | < 0.001 |
Gender (female) | 1.037 (0.665–1.618) | 0.872 | 1.192 (0.708–2.006) | 0.508 |
Sites of metastases (liver) | 1.425 (0.909–2.235) | 0.123 | 1.948 (1.088–3.487) | 0.025 |
Sites of metastases (lung) | 1.105 (0.478–2.555) | 0.815 | 0.557 (0.169–1.839) | 0.337 |
Sites of metastases (peritoneum) | 1.646 (0.900–3.011) | 0.106 | 1.002 (0.508–1.976) | 0.995 |
Local recurrence (including regional lymph node metastases) | 1.237 (0.636–2.407) | 0.531 | 1.140 (0.486–2.673) | 0.763 |
Number of metastatic sites (≥ 3) | 2.239 (1.197–4.186) | 0.012 | 2.090 (1.027–4.252) | 0.042 |
Synchronous disease (no) | 0.860 (0.533–1.390) | 0.539 | 0.815 (0.460–1.445) | 0.484 |
Tumor site (body-tail) | 1.057 (0.741–1.508) | 0.759 | 0.797 (0.533–1.192) | 0.270 |
Surgery for primary tumor (yes) | 0.782 (0.513–1.194) | 0.255 | 0.815 (0.492–1.349) | 0.425 |
CA-199 (KU/L) (> ULN) | 1.532 (0.887–2.645) | 0.126 | 1.415 (0.737–2.716) | 0.297 |
HDL-C (mmol/L) (> 0.9) | 1.560 (0.819–2.971) | 0.177 | 1.104 (0.570–2.138) | 0.770 |
ETS (≥ 20%) | 0.523 (0.315–0.868) | < 0.001 | 0.699 (0.387–1.263) | 0.014 |
ETS (as a continuous variable) | 1.015 (1.010–1.020) | < 0.001 | 1.011 (1.006–1.017) | < 0.001 |
DpR (≥ median) | 0.163 (0.092–0.290) | < 0.001 | 0.252 (0.132–0.480) | < 0.001 |
DpR (as a continuous variable) | 1.035 (1.025–1.046) | < 0.001 | 1.022 (1.013–1.031) | < 0.001 |